| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Exelixis, Inc. |
| 260 Littlefield Avenue, South San Francisco, CA 94080 * (650) 825-2200 |
| Business Description | The company is the leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. |
| Offering Information Company has | |||
| Trading As | EXEL (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/7/00 |
| Domestic Shares Offered | 9,100,000 | Offer Date | 4/10/00 |
| Foreign Shares Offered | 0 | Filing Range | $10.00 - $12.00 |
| Company Shares | 9,100,000 | Offer Price | $13.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.910 |
| Gross Proceeds | $118,300,000 | Selling | $0.550 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 40,350,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Goldman, Sachs & Co. | Lead Manager | (212) 902-5959 |
| CS First Boston | Co-manager | (212) 325-2000 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 0.000 | 0.000 | 0.000 | 2.272 | 10.510 | - | - |
| Income from Oper. | -2.986 | -5.595 | -11.966 | -15.296 | -18.767 | - | - |
| Net Income | -2.953 | -5.311 | -11.496 | -15.666 | -18.721 | - | - |
| E.P.S | -2.600 | -4.500 | -8.760 | -3.830 | -3.470 | - | - |
| Revenue Growth (%) | - | - | - | 362.588 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.32 | - | - | ||||
| Cash Flow - Inv. | -6.47 | - | - | ||||
| Cash Flow - Fin. | 17.14 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 18.90 | Current Assets | 8.03 | Current Ratio | 0.92 |
| Total Liab. | 21.73 | Current Liab. | 8.70 | Debt Ratio | 114.95% |
| Total Equity | -2.83 | Working Cap. | -0.67 | Debt to Equity Ratio | - |
| Cash | 5.40 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, capital expenditures, financing possible acquisitions and investments in technology, working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Sullivan & Cromwell |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Atlas Venture | 13.80 | |
| Oxford Bioscience Partners | 7.40 | |
| Pharmacia & Upjohn AB | 6.40 | |
| Advent International Group | 5.90 | |
| Hambrecht & Quist Capital Management, Inc. | 5.80 | |
| PaineWebber Incorporated | 5.30 | |
| Note: represents ownership of 5% or more prior to the offering. | ||